Pharmacology & Therapeutics,
Journal Year:
2024,
Volume and Issue:
258, P. 108641 - 108641
Published: April 6, 2024
Major
depression
is
an
established
risk
factor
for
subsequent
dementia,
and
in
late
life
may
also
represent
a
prodromal
state
of
dementia.
Considering
current
challenges
the
clinical
development
disease
modifying
therapies
focus
research
shifting
towards
prevention
modification
factors
to
alter
neurodegenerative
trajectory.
Understanding
mechanistic
commonalities
underlying
affective
symptoms
cognitive
decline
reveal
biomarkers
aid
early
identification
those
at
progressing
dementia
during
preclinical
phase
disease,
thus
allowing
timely
intervention.
Adult
hippocampal
neurogenesis
(AHN)
phenomenon
that
describes
birth
new
neurons
dentate
gyrus
throughout
it
associated
with
spatial
learning,
memory
mood
regulation.
Microglia
are
innate
immune
system
macrophages
central
nervous
carefully
regulate
AHN
via
multiple
mechanisms.
Disruption
both
major
microgliosis
hallmark
several
diseases.
Emerging
evidence
suggests
psychedelics
promote
neuroplasticity,
including
neurogenesis,
be
immunomodulatory.
In
this
context,
psilocybin,
serotonergic
agonist
rapid-acting
antidepressant
properties
has
potential
ameliorate
intersecting
pathophysiological
processes
relevant
narrative
review,
we
on
base
effects
psilocybin
adult
microglial
form
function;
which
suggest
modulate
mechanisms
action,
have
implications
altering
progression
from
risk.
Pharmaceutics,
Journal Year:
2023,
Volume and Issue:
15(12), P. 2773 - 2773
Published: Dec. 13, 2023
Ketamine
and
its
enantiomers
represent
an
innovative
glutamatergic
agent
as
a
treatment
for
individuals
with
treatment-resistant
depression
(TRD)
major
depressive
disorder
(MDD)
suicidal
ideation
behavior.
Intranasal
(IN)
formulations
could
allow
quick
onset
of
action
on
symptoms
well
reduction
in
side
effects
by
bypassing
the
blood–brain
barrier
compared
administration
via
intravenous
route.
The
aim
this
review
was
to
provide
up-to-date
analysis
data
efficacy
safety
IN
ketamine
esketamine
MDD.
A
systematic
following
PRISMA
guidelines
conducted.
Databases
(PubMed,
Embase,
MEDLINE,
PsycINFO,
Google
Scholar)
were
searched
capture
articles
about
or
This
highlighted
interest
routes
MDD
patients
TRD
active
ideation.
They
rapid
antidepressant
within
first
hours
after
administration.
Nevertheless,
evidence
is
stronger
than
patients.
profile
appears
be
acceptable
but
requires
further
studies,
more
accurate
delivery
device
required
ketamine.
Pharmacology & Therapeutics,
Journal Year:
2024,
Volume and Issue:
258, P. 108641 - 108641
Published: April 6, 2024
Major
depression
is
an
established
risk
factor
for
subsequent
dementia,
and
in
late
life
may
also
represent
a
prodromal
state
of
dementia.
Considering
current
challenges
the
clinical
development
disease
modifying
therapies
focus
research
shifting
towards
prevention
modification
factors
to
alter
neurodegenerative
trajectory.
Understanding
mechanistic
commonalities
underlying
affective
symptoms
cognitive
decline
reveal
biomarkers
aid
early
identification
those
at
progressing
dementia
during
preclinical
phase
disease,
thus
allowing
timely
intervention.
Adult
hippocampal
neurogenesis
(AHN)
phenomenon
that
describes
birth
new
neurons
dentate
gyrus
throughout
it
associated
with
spatial
learning,
memory
mood
regulation.
Microglia
are
innate
immune
system
macrophages
central
nervous
carefully
regulate
AHN
via
multiple
mechanisms.
Disruption
both
major
microgliosis
hallmark
several
diseases.
Emerging
evidence
suggests
psychedelics
promote
neuroplasticity,
including
neurogenesis,
be
immunomodulatory.
In
this
context,
psilocybin,
serotonergic
agonist
rapid-acting
antidepressant
properties
has
potential
ameliorate
intersecting
pathophysiological
processes
relevant
narrative
review,
we
on
base
effects
psilocybin
adult
microglial
form
function;
which
suggest
modulate
mechanisms
action,
have
implications
altering
progression
from
risk.
